A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function (Intracor)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02105870|
Recruitment Status : Unknown
Verified April 2014 by A/P Andrew Wilson, University of Melbourne.
Recruitment status was: Active, not recruiting
First Posted : April 7, 2014
Last Update Posted : April 7, 2014
Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients suffering an acute myocardial infarction.
The investigators hypothesise that treatment with intracoronary abciximab, a potent anti platelet agent, at the time of coronary stent insertion, will improve microvascular function.
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Infarction Coronary Artery Disease||Drug: Abciximab||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function|
|Study Start Date :||February 2012|
|Estimated Primary Completion Date :||June 2014|
|Estimated Study Completion Date :||June 2014|
Experimental: Intracoronary abciximab (Reopro)
Intracoronary abciximab (Reopro)
This drug will be administered intracoronary before percutaneous coronary intervention.
Other Name: Reopro
Placebo Comparator: Control group
- Index of Microvascular Resistance [ Time Frame: within 3 hours ]We will assess IMR in the catheterisation laboratory immediately before PCI, then intracoronary reopro or placebo will be administered and we will re-assess IMR 15 minutes post delivery of the study drug. Finally we will perform PCI and immediately measure IMR post-procedure.
- Incidence of periprocedural myocardial infarction [ Time Frame: within 24 hours ]We will assess for periprocedural myocardial infarction 8 to 24 hours post PCI
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02105870
|St Vincent's Hospital|
|Fitzroy, Victoria, Australia, 3101|
|Principal Investigator:||Andrew Wilson, MD PhD||University of Melbourne|